Cargando…

Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar

BACKGROUND: Peroxisome proliferator-activated receptor (PPAR) agonists may have favorable outcomes on non-alcoholic fatty liver disease. This study serves as proof of concept to evaluate whether dual PPAR-α/γ agonists improve non-invasive tests of liver steatosis and fibrosis. METHODS: This is a pos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grobbee, Esmée J., de Jong, Vivian D., Schrieks, Ilse C., Tushuizen, Maarten E., Holleboom, Adriaan G., Tardif, Jean-Claude, Lincoff, A. Michael, Schwartz, Gregory G., Castro Cabezas, Manuel, Grobbee, Diederick E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665379/ https://www.ncbi.nlm.nih.gov/pubmed/36378671 http://dx.doi.org/10.1371/journal.pone.0277706

Ejemplares similares

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
por: Koomen, Jeroen V., et al.
Publicado: (2019)

A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey
por: Driessen, Stan, et al.
Publicado: (2023)

Referral care paths for non‐alcoholic fatty liver disease—Gearing up for an ever more prevalent and severe liver disease
por: van Dijk, Anne‐Marieke, et al.
Publicado: (2021)

Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
por: Dietz, Michel, et al.
Publicado: (2012)

Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice
por: Boujon, Valérie, et al.
Publicado: (2019)

Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease
por: van Son, Koen C., et al.
Publicado: (2023)

Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis
por: Zhu, Kun, et al.
Publicado: (2018)

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study
por: Ruilope, Luis, et al.
Publicado: (2014)

Modulation of liver steatosis by miR-21/PPARα
por: Rodrigues, Pedro M., et al.
Publicado: (2018)

Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Houttu, Veera, et al.
Publicado: (2021)

Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease
por: Van Dijk, Anne-Marieke, et al.
Publicado: (2021)

The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease
por: Grefhorst, Aldo, et al.
Publicado: (2021)

Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia
por: Chen, Yan, et al.
Publicado: (2017)

The role of the gut microbiome and exercise in non-alcoholic fatty liver disease
por: Houttu, Veera, et al.
Publicado: (2020)

Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis
por: Houttu, Veera, et al.
Publicado: (2022)

The Heart in the Time of the ‘Coronavirus’
por: Perel, Pablo, et al.
Publicado: (2020)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease
por: Li, Yaru, et al.
Publicado: (2020)

Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα
por: Wei, Xiaohui, et al.
Publicado: (2022)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Alnimer, Lynna, et al.
Publicado: (2023)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Nogami, Asako, et al.
Publicado: (2023)

Adherence to Drinking Guidelines and Reasons for Alcohol Consumption Cessation in the Southern Cone of Latin America – Findings from the CESCAS Study
por: van de Luitgaarden, Inge A. T., et al.
Publicado: (2021)

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
por: Hansen, Barbara C, et al.
Publicado: (2011)

Cardiovascular guidelines based on high-quality evidence: Are we getting there?
por: van Dijk, Wouter B, et al.
Publicado: (2019)

Urinary Ethyl Glucuronide Can Be Used as a Biomarker of Habitual Alcohol Consumption in the General Population
por: van de Luitgaarden, Inge A T, et al.
Publicado: (2019)

Antenatal exposure to second hand smoke of non-smoking mothers and growth rate of their infants
por: Soesanti, Frida, et al.
Publicado: (2019)

PPARγ Variant Influences Angiographic Outcome and 10-Year Cardiovascular Risk in Male Symptomatic Coronary Artery Disease Patients
por: Regieli, Jakub J., et al.
Publicado: (2009)

Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
por: Melton, Phillip E., et al.
Publicado: (2023)

Alcoholic liver steatosis in mice is aggravated by low-protein diet and reversed by FXR agonist
por: Lívero, Francislaine Aparecida dos Reis, et al.
Publicado: (2012)

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis
por: Zhang, Zhuo-Ya, et al.
Publicado: (2023)

Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver
por: Rogue, Alexandra, et al.
Publicado: (2010)

Liver-Specific Deletion of Mouse CTCF Leads to Hepatic Steatosis via Augmented PPARγ Signaling
por: Choi, Yeeun, et al.
Publicado: (2021)

Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations
por: van Dijk, Anne-Marieke, et al.
Publicado: (2021)

Comparison of hepatic steatosis index as noninvasive diagnostic tool and liver ultrasound for non-alcoholic steatosis in the adult population
por: Khani, Vahid, et al.
Publicado: (2022)

Country Characteristics and Variation in Diabetes Prevalence among Asian Countries – an Ecological Study
por: Widyahening, Indah, et al.
Publicado: (2019)

Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study
por: Ciećko-Michalska, Irena, et al.
Publicado: (2018)

The effect of non-organophosphate household pesticides exposure during pregnancy on infants birth sizes and growth rate: a cohort study
por: Soesanti, Frida, et al.
Publicado: (2020)

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
por: Vali, Yasaman, et al.
Publicado: (2022)

Honokiol: A non-adipogenic PPARγ agonist from nature()
por: Atanasov, Atanas G., et al.
Publicado: (2013)

Non-contrasted Computed Tomography for the Accurate Measurement of Liver Steatosis in Obese Patients
por: Shores, Nathan J., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p7v1395u3lfoa08fe34h7s7g4c